ArticleBMC microbiology2022
Insights on the performance of phenotypic tests versus genotypic tests for the detection of carbapenemase-producing Gram-negative bacilli in resource-limited settings.
Article in BMC microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Phenotypic and molecular characterization of carbapenem resistance among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii.BMC microbiology · 2026Article
- Comparative Evaluation of Real-Time PCR, Immunochromatographic Assay, and Modified Carbapenem Inactivation Method for Carbapenemase Detection in Enterobacterales Isolates.International journal of molecular sciences · 2026Article
- Multidrug-resistantNew microbes and new infections · 2026Article
- Rapid Detection of Carbapenemase-Producing Enterobacterales Using a Luminescent Whole-Cell Biosensor.ACS infectious diseases · 2026Article
- Article
- Rapid 65-min SYBR-Green PCR Assay for Carbapenem ResistantMicroorganisms · 2025Article
- Pristinamycin-antibiotic combinations against methicillin-resistant Staphylococcus aureus recovered from skin infections.BMC infectious diseases · 2025Article
- Next-Gen Nano Biosensor Technologies to Monitor Carbapenem Resistance for Personalized Medicine.Indian journal of microbiology · 2025Article
- Genomic analysis of non-carbapenem drug-resistant Gram-negative bacteria from advanced chronic liver disease (ACLD) patients suggests no evidence for in-house transmissions.Frontiers in microbiology · 2025Article
- Evaluation of PhenoMATRIX® PLUS for the culture-based rectal screening of CPOs, ESBL-E,Frontiers in microbiology · 2025Article
- A prospective study on the evaluation of a novel immunochromatographic card for the rapid detection of five carbapenemase enzymes in metallo-beta-lactamase producers.Access microbiology · 2025Article
- BBB-Crossing Ionizable Upconversion Nanoparticles for Synergistic Therapy of Carbapenem-Resistant Central Nervous System Infection.Research (Washington, D.C.) · 2025Article
- Analysis of a simple disk diffusion method to evaluate ceftazidime-avibactam/aztreonam combination synergism against New Delhi metallo-beta-lactamase-producing clinical isolates.Access microbiology · 2025Article
- Combined Use of Phenotypic Screening and of a Novel Commercial Assay (REALQUALITY Carba-Screen) for the Rapid Molecular Detection of Carbapenemases: A Single-Center Experience.Diagnostics (Basel, Switzerland) · 2024Article
- Evaluation of fortimicin antibiotic combinations against MDR Pseudomonas aeruginosa and resistome analysis of a whole genome sequenced pan-drug resistant isolate.BMC microbiology · 2024Article
- Prevalence of Antimicrobial Resistance Among the Hydrogen Sulfide Producing Bacteria Isolated on XLD Agar from the Poultry Fecal Samples.Applied biochemistry and biotechnology · 2024Article
- Propranolol restores susceptibility of XDR Gram-negative pathogens to meropenem and Meropenem combination has been evaluated with either tigecycline or amikacin.BMC microbiology · 2023Article
- Transferable IncX3 plasmid harboring blaMolecular biology reports · 2023Article
- Phenotypic and genotypic detection of resistance mechanisms in carbapenem-resistant gram-negative bacteria isolated from Egyptian ICU patients with first emergence of NDM-1 producingIranian journal of microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbapenemase-producing Gram-negative (CPGN) bacteria impose life-threatening infections with limited treatment options. Rigor and rapid detection of CPGN-associated infections is usually associated with proper treatment and better disease prognosis. Accordingly, this study aimed at evaluating the phenotypic methods versus genotypic methods used for the detection of such pathogens and determining their sensitivity/specificity values.
methodsA total of 71 CPGN bacilli (30 Enterobacterales and 41 non-glucose-fermenting bacilli) were tested for the carbapenemase production by the major phenotypic approaches including, the modified Hodge test (MHT), modified carbapenem inactivation method (mCIM), combined disk test by EDTA (CDT) and blue-carba test (BCT). The obtained results were statistically analyzed and correlated to the obtained resistant genotypes that were determined by using polymerase chain reactions (PCR) for the detection of the major carbapenemase-encoding genes covering the three classes (Class A, B, and D) of carbapenemases.
resultsIn comparison to PCR, the overall sensitivity/specificity values for detection of carbapenemase-producing organism were 65.62%/100% for MHT, 68.65%/100% for mCIM, 55.22%/100% for CDT and 89.55%/75% for BCT. The sensitivity/specificity values for carbapenemase-producing Enterobacterales were, 74%100% for MHT, 51.72%/ 100% for mCIM, 62.07%/100% for CDT and 82.75%/100% for BCT. The sensitivity/specificity values for carbapenemase-producing non-glucose fermenting bacilli were, 62.16%/100% for MHT, 81.57%/100% for mCIM, 50/100% for CDT and 94.74%/66.66% for BCT. Considering these findings, BCT possess a relatively high performance for the efficient and rapid detection of carbapenemase producing isolates. Statistical analysis showed significant association (p < 0.05) between bla
conclusionThe current study provides an update on the performance of the phenotypic tests which are varied depending on the tested bacterial genera and the type of the carbapenemase. The overall sensitivity/specificity values for detection of CPO were 65.62%/100% for MHT, 68.65%/100% for mCIM, 55.22%/100% for CDT and 89.55%/75% for BCT. Based on its respective diagnostic efficiency and rapid turnaround time, BCT is more likely to be recommended in a resource-limited settings particularly, when molecular tests are not available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.